1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Intra-Cellular Poised To Add MDD To Caplyta’s Label

Second Phase III Is Positive

 
• By Joseph Haas

Caplyta succeeded in a second Phase III study as adjunctive therapy for major depression, putting the schizophrenia/bipolar disorder drug on track for sNDA filing later in 2024.

Intra-Cellular will file lumateperone for approval in adjunctive MDD

With a second successful Phase III readout in major depressive disorder this quarter for Caplyta (lumateperone), Intra-Cellular Therapies, Inc. said on 18 June that it intends to seek what would be the drug’s third indication this year, and anticipates approval in the second half of 2025. While Caplyta works toward blockbuster status as a therapy for schizophrenia and bipolar I/II disorder, analysts said an MDD indication should add billions more to its revenue potential.

Key Takeaways

  • Intra-Cellular followed April’s successful Phase III trial of Caplyta in depression with a second trial virtually replicating those results.

  • The New York firm plans...

CEO Sharon Mates told a same-day call that Intra-Cellular will file a supplemental new drug application with the US Food and Drug Administration based on data from the two Phase...

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.